A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants

NCT06890611 · Completed

Last updated 2026-05-28

This study tests how the body processes the drug bimagrumab, alone and combined with tirzepatide, in healthy participants.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 125 people

Who can join Ages 18–64 · all sexes Healthy volunteers accepted.

Timeline Started 2025-03 · est. completion 2025-09

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06890611 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.

Treatments tested

Bimagrumab also known as LY3985863, BYM338, VER201 Drug

Administered SC
Tirzepatide also known as LY3298176 Drug

Administered SC
Bimagrumab + Tirzepatide Coformulation also known as LY900042 Drug

Administered SC

Main thing measured	Pharmacokinetics (PK): Maximum Concentration (Cmax) of Bimagrumab Test Material
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06890611 ↗